Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-10T13:28:18.821Z Has data issue: false hasContentIssue false
  • English
  • Français

Intermittent administration of human parathyroid fragment (hPTH 1-37) on calcium and phosphorus homeostasis and bone markers in resting horses: a preliminary study

Published online by Cambridge University Press:  09 March 2007

I Vervuert ,
K Von Scheidt ,
S Winkelsett ,
WG Forssmann  and
M Coenen
I Vervuert*
Affiliation:
Institute for Animal Nutrition, University of Veterinary Medicine Hannover, Foundation, Bischofsholer Damm 15, D-30173 Hannover, Germany
K Von Scheidt
Affiliation:
Institute for Animal Nutrition, University of Veterinary Medicine Hannover, Foundation, Bischofsholer Damm 15, D-30173 Hannover, Germany
S Winkelsett
Affiliation:
Institute for Animal Nutrition, University of Veterinary Medicine Hannover, Foundation, Bischofsholer Damm 15, D-30173 Hannover, Germany
WG Forssmann
Affiliation:
IPF-Pharmaceuticals, Feodor-Lynen-Str. 31, D-30625 Hannover, Germany
M Coenen
Affiliation:
Institute for Animal Nutrition, University of Veterinary Medicine Hannover, Foundation, Bischofsholer Damm 15, D-30173 Hannover, Germany
*
*ingrid.vervuert@tiho-hannover.de
Get access

Abstract

Parathyroid hormone (PTH) has been shown to have anabolic and catabolic effects on the skeleton, and in young racing horses the anabolic effects of PTH on bone might be of great importance in reducing the risk of skeletal injury during race training. The aim of this pilot study was to elucidate the effects of intermittent exogenous application of human parathyroid fragment (hPTH 1-37) on calcium homeostasis and bone turnover in resting horses. Five horses were used in this study. Horses were treated subcutaneously with hPTH (hPTH 1-37, 0.5 μg kg−1 BW) daily at 600 h over a period of 28 days. A foregoing control trial was conducted under the identical test protocol without hPTH application. Blood samples were taken at defined times for the control and hPTH treatment to analyze ionized Ca (Ca++, AVL), total Ca (AAS), inorganic Pi (flame photometry), intact PTH (RIA), osteocalcin (ELISA) and ICTP (carboxyterminal telopeptide of type-I collagen, RIA). Eight hours after hPTH application, blood ionized Ca++ (days 1 and 28) and plasma Pi (days 1–28) increased significantly in comparison to the control. At day 1, 8 h after hPTH application, the decrease in intact plasma PTH was more pronounced after hPTH treatment than in the control, and plasma PTH levels were higher after treatment at day 14 (16 h post-injection, P<0.05), day 18 (16 h post-injection, ns) and day 24 (0 h post-injection). There were no treatment-related differences in total plasma Ca and bone markers. Intermittent PTH administration in healthy horses affected Ca and P homeostasis as well as endogenous PTH secretion, but bone turnover was not affected during the treatment period of 28 days.

Type
Research Article
Information
Equine and Comparative Exercise Physiology , Volume 2 , Issue 4 , November 2005 , pp. 245 - 251
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Hock, JM, Fitzpatrick, LA and Bilezikian, JP (2002). Actions of parathyroid hormone. In: Bilezikian, JP, Raisz, LG, Rodan, GA (eds), Principles of Bone Biology, 2nd edn. San Diego, CA: Academic Press, pp. 463–482.CrossRefGoogle Scholar
2Tam, CS, Heersche, JNM, Murray, TM and Parsons, JA (1982). Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110: 506–512.CrossRefGoogle ScholarPubMed
3Hock, JM and Gera, I (1992). Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. Journal of Bone Mineral Research 7: 65–72.CrossRefGoogle ScholarPubMed
4Backstrom, KC, Bertone, AL, Wisner, ER and Weisbrode, SE (2004). Response of induced bone defects in horses to collagen matrix containing the human parathyroid hormone gene. American Journal of Veterinary Research 65: 1223–1232.CrossRefGoogle ScholarPubMed
5Podbesek, R, Edouard, C, Meunier, PJ, Parsons, JA, Reeve, J, Stevenson, RW and Zanelli, JM (1983). Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in Greyhounds. Endocrinology 112: 1000–1006.CrossRefGoogle Scholar
6Riond, JL, Goliat-von Fischer, I, Küffer, BToromanoff, A and Forrer, R (1998). Influence of the dosing frequency of parathyroid hormone (1-38) on its anabolic effect in bone and on the balance of calcium, phosphorus and magnesium. Zeitschrift für Ernährungswissenschaften 37: 183–189.Google ScholarPubMed
7Finkelstein, JS, Klibanski, A, Schaefer, EH, Hornstein, MD, Schiff, I and Neer, RM (1994). Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. The New England Journal of Medicine 331: 1618–1623.CrossRefGoogle ScholarPubMed
8Lindsay, R, Nieves, J, Formica, C, Henneman, E, Woelfert, L, Shen, V, Dempster, D and Cosman, F (1997). Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350: 550–555.CrossRefGoogle ScholarPubMed
9Finkelstein, JS, Klibanski, A, Arnold, A, Toth, TL, Hornstein, MD and Neer, RM (1998). Prevention of estrogen deficiency-related bone loss with human parathyroid hormone (1-34). Journal of American Medical Association 280: 1067–1073.CrossRefGoogle ScholarPubMed
10Lane, NE, Sanchez, S, Modin, GW, Genant, HK, Pierini, E and Arnaud, C (1998). Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Journal of Clinical Investigation 102: 1627–1633.CrossRefGoogle ScholarPubMed
11Neer, RM, Arnaud, CD, Zanchetta, JR, Prince, R, Gaich, GA, Reginster, JY, Hodsman, AB, Eriksen, EF, Ish-Shalom, S, Genant, HK, Wang, O and Mitlak, BH (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. The New England Journal of Medicine 344: 1434–1441.CrossRefGoogle ScholarPubMed
12Buckingham, SHW and Jeffcott, LB (1991). Osteopenic effects of forelimb immobilisation in horses. Veterinary Record 128: 370–373.CrossRefGoogle ScholarPubMed
13Geor, R, Hope, E, Lauper, L, Piela, S, Klassen, J, King, V and Murphy, M (1995). Effect of glucocorticoids on serum osteocalcin concentration in horses. American Journal of Veterinary Research 56: 1201–1207.CrossRefGoogle ScholarPubMed
14Nielsen, BD, Potter, GD, Greene, LW, Morris, EL, Murray-Gerzik, M, Smith, WB and Martin, MT (1998). Characterization of changes related to mineral balance and bone metabolism in the young racing Quarter Horse. Journal of Equine Veterinary Science 18: 190–200.CrossRefGoogle Scholar
15Nielsen, BD, Potter, GD, Morris, EL, Odom, TW, Senor, DM, Reynolds, JA, Smith, WB and Martin, MT (1997). Changes in the third metacarpal bone and frequency of bone injuries in young Quarter Horses during race training–observations and theoretical considerations. Journal of Equine Veterinary Science 17: 541–549.CrossRefGoogle Scholar
16GEH: Gesellschaft für Ernährungsphysiologie der Haustiere, (1994). Empfehlungen zur Energie-und Nährstoffversorgung der Pferde. Frankfurt (Main): DLG Verlag.Google Scholar
17Bringhurst, FR and Strewler, GJ (2002). Renal and skeletal actions of parathyroid hormone (PTH) and PTH-related protein. In: Bilezikian, JP, Raisz, LG and Rodan, GA (eds), Renal and Skeletal Actions of Parathyroid Hormone (PTH) and PTH-Related Protein, 2nd edn. San Diego: Academic Press, pp. 483–514.Google Scholar
18Hodsman, AB, Hanley, DA, Watson, PH and Fraher, LJ (2002). Parathyroid hormone. In: Bilezikian,, JP, Raisz, LG and Rodan, GA (eds), Principles of Bone Biology, 2nd edn. San Diego, CA: Academic Press, pp. 1305–1324.CrossRefGoogle Scholar
19Raulais, D, Desplan, C, Monet, JD, Boccard, B and Milhaud, G (1981). Immunochemical and biological properties of horse parathyroid hormone. Proceedings of the Society for Experimental Biology and Medicine 167: 542–546.CrossRefGoogle ScholarPubMed
20Orwell, ES, Scheele, WH, Paul, S, Adami, S, Syversen, U, Diez–Perez, A, Kaufman, JM, Clancy, AD and Gaich, GA (2003). The effect of teriparatide (human parathyroid hormone [1-34]) therapy on bone density in men with osteoporosis. Journal of Bone Mineral Research 18: 9–17.CrossRefGoogle Scholar
21Breidenbach, A, Schlumbohm, C and Harmeyer, J (1998). Peculiarities of vitamin D and of the calcium and phosphate homeostatic system in horses. Veterinary Research 29: 173–186.Google ScholarPubMed
22Lindsay, R, Nieves, J, Henneman, E, Shen, V and Cosman, F (1993). Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone (1-34): kinetics and biochemical response in estrogenized osteoporotic patients. Journal of Clinical Endocrinology and Metabolism 77: 1535–1539.Google ScholarPubMed
23Cosman, F, Shen, V, Herrington, B and Lindsay, R (1991). Response of the parathyroid gland to infusion of human parathyroid hormone (1-34) [PTH-(1-34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH (1-84) assay. Journal of Clinical Endocrinology and Metabolism 73: 1345–1351.CrossRefGoogle ScholarPubMed
24Fischer, JA, Blum, JW, Born, W, Dambacher, MA and Dempster, DW (1982). Regulation of parathyroid hormone secretion in vitro and in vivo. Calcified Tissue International 34: 313–316.CrossRefGoogle ScholarPubMed
25Fujimi, T, Baba, H, Fukase, M and Fujita, T (1991). Direct inhibitory effect of amino-terminal parathyroid hormone fragment [PTH(1-34)] on PTH secretion from bovine parathyroid primary cultured cells in vitro. Biochemical Biophysical Research Communications 15: 953–958.CrossRefGoogle Scholar
26Mizgala, CL and Quamme, GA (1985). Renal handling of phosphate. Physiological Reviews 65: 431–466.CrossRefGoogle ScholarPubMed
27Fox, J, Miller, MA, Stroup, GB, Nemeth, EF and Miller, SC (1997). Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion. Bone 21: 163–169.CrossRefGoogle ScholarPubMed
28Risteli, L and Risteli, J (1993). Biochemical markers of bone metabolism. Annals of Medicine 25: 385–393.CrossRefGoogle ScholarPubMed
29Lepage, OM, Marcoux, M and Tremblay, A (1990). Serum osteocalcin or bone gla-protein, a biochemical marker for bone metabolism in horses: differences in serum levels with age. Canadian Journal of Veterinary Research 54: 223–226.Google ScholarPubMed
30Price, JS, Jackson, BF, Eastell, R, Goodship, AE, Blumsohn, A, Wright, I, Stoneham, S, Lanyon, LE and Russel, RGG (1995). Age related changes in biochemical markers of bone metabolism in horses. Equine Veterinary Journal 27: 201–207.CrossRefGoogle ScholarPubMed
31Black, A, Schoknecht, PA, Ralston, SL and Shapses, SA (1999). Diurnal variation and age differences in the biochemical markers of bone turnover. Journal of Animal Science 77: 75–83.CrossRefGoogle ScholarPubMed
32Price, JS, Jackson, BF, Gray, JA, Harris, P, Wright, IM, Pfeiffer, DU, Robins, SP, Eastell, R and Ricketts, SW (2001). Biochemical markers of bone metabolism in growing thoroughbreds: a longitudinal study. Research in Veterinary Science 71: 37–44.CrossRefGoogle ScholarPubMed